Cardio Diagnostics
Develops genetic-epigenetic blood tests and clinical intelligence for coronary heart disease.
Something off on this page? Send us feedback.
Profile
Provides prescription blood tests for coronary-heart-disease risk assessment and detection, combining genetic and epigenetic biomarkers with predictive models. Revenue is reported entirely in product testing, while clinical adoption depends on reimbursement, guidelines and provider workflow integration.
Transforms genetic, DNA-methylation and clinical data into biomarker panels, laboratory assays and interpretive models for prescription blood tests. Epi+Gen CHD assesses coronary-heart-disease event risk, while PrecisionCHD detects and helps manage the disease; Actionable Clinical Intelligence links patient profiles to modifiable pathways.
Operates the clinical tests as laboratory-developed tests through a high-complexity CLIA-certified, state-licensed laboratory, assembling blood-collection kits internally and sourcing proprietary genetic and DNA-methylation components from outside manufacturers. Commercial activity is primarily U.S.-focused across providers, health systems, employers and payors, with a partner-led implementation in India.
Extends the portfolio with HeartRisk population-risk intelligence and CardioInnovate360 biopharma research support. Broad adoption depends on payor coverage, clinical-guideline inclusion, provider-workflow integration and continuing evidence; core patent rights are exclusively licensed from the University of Iowa Research Foundation.
Company facts
Key statistics
Year to date −35.9% · Average volume (30d) 84.7K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | — | −$0.51 | — | — | $5.4K | — | +7.83% |
| May 15, 2026Q1 FY26 | — | −$0.63 | — | — | $2.7K | — | −10.32% |
| Mar 13, 2026Q4 FY25 | −$1.80 | −$0.80 | +55.6% | $250.0K | $3.6K | −98.6% | −13.93% |
| Nov 12, 2025Q3 FY25 | −$1.80 | −$0.98 | +45.6% | $150.0K | $2.9K | −98.1% | −9.09% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $940 | $7.5K | $2.9K | $3.6K | $2.7K | $5.4K | |
| Gross profit | $940 | $7.5K | $2.9K | $3.6K | −$92.0K | $5.4K | |
| Operating income | −$1.6M | −$1.7M | −$1.7M | −$1.5M | −$1.8M | −$1.5M | |
| Net income | −$1.6M | −$1.7M | −$1.7M | −$1.5M | −$1.8M | −$1.5M | |
| Diluted EPS | −$0.97 | −$0.97 | −$0.98 | −$0.80 | −$0.63 | −$0.51 | |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | -3,431.8% | 100.0% | |
| Operating margin | -173,463.8% | -22,457.5% | -59,950.9% | -41,159.5% | -66,598.4% | -27,950.5% |
Fiscal years (4-quarter sums)FY21 $901 · FY22 $950 · FY23 $17.1K · FY24 $34.9K · FY25 $14.8K
Balance sheet, Jun 30, 2026Cash & short-term investments $5.6M · Total debt $369.7K · Total assets $7.9M · Shareholders' equity $7.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 2.96M · Float 2.83M · 95.8% free float
Insiders — no current Form 4 position.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Jane Street Group, LLC | 81.3K | 2.75% | 13F | May 12, 2026 |
| HRT Financial LP | 62.5K | 2.11% | 13F | May 14, 2026 |
| BlackRock, Inc. | 34.7K | 1.17% | 13F | May 13, 2026 |
| Geode Capital Management, LLC | 32.2K | 1.09% | 13F | May 15, 2026 |
| Vanguard Capital Management LLC | 20.2K | 0.68% | 13F | May 15, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Quest Diagnostics
Advanced blood panels contest preventive cardiovascular-risk testing.
- Labcorp
NMR lipid profiling contests blood-based cardiovascular-risk testing.
- Abbott
Cardiac biomarker assays contest CHD-risk and acute-detection testing.
- GE HealthCare
Cardiac CT contests coronary-disease diagnostic workflows.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cardio Diagnostics | $1.85 | +1.65% | $5.5M | — | — | 378.9 | −28.3% |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| GE HealthCare | $71.73 | −0.01% | $32.40B | 20.8 | 13.8 | 1.6 | +5.8% |
| Median | 26.7 | 18.5 | 2.1 | +8.0% |